Advanced Micro Devices (NASDAQ:AMD)- Active Wrathful Watching Stock: Neothetics, Inc. (NASDAQ:NEOT)

Advanced Micro Devices, Inc. (NASDAQ:AMD) [Trend Analysis] retains strong position in active trade, as shares scoring -0.17% to $11.58 in active trade session, while looking at the shares volume, around 32.23 Million shares have changed hands in this session. There’s a reason why every news story you read at PCWorld includes a “Why this matters” or “The impact on you” paragraph: Context is important. Without proper context, news and numbers are just characters on a screen and raw information without a wider look at what it actually means often results in misinterpretation and FUD.

Case in point: A recent post by Parsec, a cloud game streaming company, titled “The Loyalty To AMD’s GPU Product Among AMD CPU Buyers Is Decreasing.” Parsec pulls an abundance of data from PCPartPicker builds to show that AMD CPU sales have declined precipitously over the past six months, and the number of AMD CPU buyers who also bought Radeon graphics cards dropped as well. The firm has institutional ownership of 70.80%, while insider ownership included 0.60%. AMD attains analyst recommendation of 2.60 with week’s performance of 8.63%. Investors looking further ahead will note that the Price to next year’s EPS is 126.70%.

Shares of Neothetics, Inc. (NASDAQ:NEOT) [Trend Analysis] swings enthusiastically in regular trading session, it an advance of 19.79% to close at $1.15. Neothetics, Inc. (NEOT) reported that initiation of the Phase 2 proof of concept trial, LIPO-202-CL-31, for LIPO-202 for the reduction of submental subcutaneous fat.“The initiation of our Phase 2 proof of concept trial for LIPO-202 for the reduction of submental fat is a important milestone for Neothetics,” said Kim Kamdar, Ph.D., a member of Neothetics’ Operating Committee and Board of Directors.

“We continue to believe LIPO-202 could have exceptional impact in the submental fat reduction market.”LIPO-202-CL-31 is a multi-center, randomized, double-blind, placebo-controlled Phase 2 proof of concept trial to assess the safety and efficacy of two doses of LIPO-202 versus placebo for the reduction of submental bulging due to subcutaneous fat.

The trial is expected to enroll a total of 150 patients at approximately ten sites across the United States. Subjects will receive up to 30 subcutaneous injections of LIPO-202 or placebo once a week for eight weeks. Subjects will be randomized 1:1:1 and receive either 0.3 mcg, or 3.0 mcg dose of LIPO-202, or placebo. Follow up visits to access safety and efficacy will occur one week and four weeks post the last treatment. The stock is going forward its fifty-two week low with 116.17% and lagging behind from its 52-week high price with -38.83%. NEOT last month stock price volatility remained 10.49%.


About Blake Escott

Blake Escott holds junior writer position in SWR. Before joining Streetwise Report, he was a freelance content Writer. He has high-level copywriting experience and particularly experienced in proofreading and editing. He covers news about different companies including all US market sectors. Interests: Commodities, Energy stocks, Sector-wise Stocks analysis, Utilities

Leave a Reply

Your email address will not be published. Required fields are marked *